Background: A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to demonstrate the efficacy and a safety of Milvexian, an Oral Factor XIa Inhibitor, after a recent Acute Coronary Syndrome Sponsor: Janssen, Bristol Myers Squibb, Johnson-Johnson Trial Registration No: NCT05754957 (clinicaltrials.gov) Link Trial Status: Recruiting Enrolling Centers: Worldwide: multicentric Core Study Team: